| Aug 15 |
Fate Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 14 |
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
|
| Aug 13 |
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 13 |
Fate Therapeutics GAAP EPS of -$0.33 beats by $0.13, revenue of $6.77M beats by $5.22M
|
| Aug 13 |
Fate Therapeutics: Q2 Earnings Snapshot
|
| Aug 13 |
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
|
| Aug 2 |
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
|
| Jul 31 |
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
|
| Jul 31 |
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
|
| Jul 21 |
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
|
